Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
about
Alpha-glucosidase inhibitors for type 2 diabetes mellitusAcarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomesGlucose supply and insulin demand dynamics of antidiabetic agents.The post-prandial state and cardiovascular disease: relevance to diabetes mellitus.Pharmacotherapy of type 2 diabetes mellitus.Effects of current therapeutic interventions on insulin resistance.Cyanidin-3-rutinoside alleviates postprandial hyperglycemia and its synergism with acarbose by inhibition of intestinal α-glucosidase.Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysisGlycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum.Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes.Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study.Cardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus.Acarbose monotherapy and weight loss in Eastern and Western populations with hyperglycaemia: an ethnicity-specific meta-analysis.Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus.Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study.New treatments for patients with type 2 diabetes mellitusEffect of Metformin, Acarbose and Their Combination on the Serum Visfatin Level in Nicotinamide/Streptozocin-Induced Type 2 Diabetic Rats.Acarbose: its role in the treatment of diabetes mellitus.Inhibitory activities of cyanidin and its glycosides and synergistic effect with acarbose against intestinal α-glucosidase and pancreatic α-amylase.Aqueous extracts of husks of Plantago ovata reduce hyperglycaemia in type 1 and type 2 diabetes by inhibition of intestinal glucose absorption.Effect of O-methylated and glucuronosylated flavonoids from Tamarix gallica on α-glucosidase inhibitory activity: structure-activity relationship and synergistic potential.Miglitol combined with metformin improves glycaemic control in type 2 diabetes.[Reducing postprandial glucose levels. Glucosidase antagonists].Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters.Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.Effects of chronic acarbose treatment on adipocyte insulin responsiveness, serum levels of leptin and adiponectin and hypothalamic NPY expression in obese diabetic Wistar rats.Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database.Diabetes mellitus in a patient with glycogen storage disease type Ia: a case report.Efficacy and safety of acarbose chewable tablet in patients with type 2 diabetes: a multicentre, randomized, double-blinded, double-dummy positive controlled trial.
P2860
Q24246908-9A3F5016-B212-4FFD-BC94-27A14BA9D607Q26778095-9EB0D7F3-33A2-4C4F-B3B3-8793E0AF1B1FQ33828255-FEDC3D50-6C5A-437B-86C1-BA1AD0EFAEF4Q33883730-31E9B4C8-C215-4215-8AEB-E398CB1A8E1CQ33992531-61447BDF-931D-4762-BF9B-A2FFDC170F74Q34163110-7C8C2915-50A6-4471-8039-D89795B2A81AQ35082857-3224F024-42A1-41F4-B540-93FC2A92178DQ35592932-B2741FEA-D3F7-415D-9F4C-07875FC12864Q36194911-99E6DBD2-B9EB-4232-8B75-434E75146CFDQ36816194-DAAE805B-767A-48CE-B94A-80AD4C7A46C5Q37076275-A4A12C00-EB29-4DE6-AFB1-8616E68DF174Q37473701-287A9EA6-6AC4-466E-A3D7-7644AE3F83AEQ38068353-1B7BF598-2E71-46F0-9346-BC764E33F35CQ38213904-5031FDB3-2EBB-44E4-A435-425FF00E4BBAQ38259933-905B5246-3649-44EE-85BA-4D201704F252Q38323835-4985F6F6-BA96-4721-9A4A-E200FC828A9DQ38646293-58DC557D-2650-4C94-A0FE-B3B2AD6ABD3BQ39719551-49528880-55ED-4795-B4B5-FD3EE4811B14Q41206503-F75822EA-B747-4A2F-89CE-392136A789DCQ42023231-F1A86B96-31C0-4C55-8A56-B8B35D1A506FQ42798556-85A918CF-B366-4A80-87F6-2896C78897C6Q43029021-00D8B47F-4E95-476D-9C2D-BB1A14F5CF44Q43795776-3CA44AB4-25EC-4B2C-8299-3C98BD4C8D22Q44032473-20111C06-EF56-43DE-B896-201EE5FFB373Q44107437-1EBDB4EB-8568-411E-855D-C4230F185B12Q44948846-A628AB2C-1EF6-4389-A238-C77F1A9356DBQ46740958-84B69FA6-6F06-46FE-8F20-4A3344902DB5Q46783489-9B6304FD-EBBE-41B6-8580-9846977741A8Q47147806-D973EFBB-33FE-4C50-A6BC-81DE6647EE2CQ50995567-6D16DFF3-7DDC-4608-89B5-0566E71754BE
P2860
Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
description
1991 nî lūn-bûn
@nan
1991 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Therapeutic potentials of acar ...... ently treated with diet alone.
@ast
Therapeutic potentials of acar ...... ently treated with diet alone.
@en
type
label
Therapeutic potentials of acar ...... ently treated with diet alone.
@ast
Therapeutic potentials of acar ...... ently treated with diet alone.
@en
prefLabel
Therapeutic potentials of acar ...... ently treated with diet alone.
@ast
Therapeutic potentials of acar ...... ently treated with diet alone.
@en
P2093
P356
P1433
P1476
Therapeutic potentials of acar ...... ently treated with diet alone.
@en
P2093
Hanefeld M
Schollberg K
Spengler M
Wargenau M
P304
P356
10.2337/DIACARE.14.8.732
P407
P577
1991-08-01T00:00:00Z